Antidepressant-Like Effect of Ropren® in β-Amyloid-(25–35) Rat Model of Alzheimer’s Disease with Altered Levels of Androgens

Molecular Neurobiology

Volumn 54, Issue 4, 2017, Pages 2611-2621

  Soultanov, Vagif ^a   Fedotova, Julia ^b,c,d   Nikitina, Tamara ^c   Roschin, Victor ^e   Ordyan, Natalia ^b   Hritcu, Lucian ^f  

^a Biotechnology Company   (Australia)

^b PAVLOV INSTITUTE OF PHYSIOLOGY   (Russian Federation)

^c SECHENOV INSTITUTE OF EVOLUTIONARY PHYSIOLOGY AND BIOCHEMISTRY   (Russian Federation)

^d ITMO UNIVERSITY   (Russian Federation)

^e SAINT PETERSBURG STATE FOREST TECHNICAL UNIVERSITY   (Russian Federation)

^f ALEXANDRU IOAN CUZA UNIVERSITY OF IASI   (Romania)

Author keywords

Alzheimer s disease; Depression like behavior; Gonadectomy; Polyprenols; Ropren ; Testosterone

Indexed keywords

AMYLOID BETA PROTEIN[25-35]; ANDROGEN; ANTIDEPRESSANT AGENT; CORTICOSTERONE; ROPREN; TESTOSTERONE; TESTOSTERONE PROPIONATE; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (25-35); PEPTIDE FRAGMENT; PLANT EXTRACT;

ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DEPRESSION; DRUG EFFECT; FORCED SWIM TEST; GROOMING; IMMOBILITY; LOCOMOTION; MALE; NONHUMAN; OPEN FIELD TEST; RAT; RAT MODEL; REARING; TESTOSTERONE BLOOD LEVEL; ANIMAL; COMPLICATION; DISEASE MODEL; METABOLISM; SWIMMING; WISTAR RAT;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANDROGENS; ANIMALS; ANTIDEPRESSIVE AGENTS; CORTICOSTERONE; DEPRESSION; DISEASE MODELS, ANIMAL; MALE; PEPTIDE FRAGMENTS; PLANT EXTRACTS; RATS, WISTAR; SWIMMING; TESTOSTERONE;

EID: 84961208086     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-016-9848-8     Document Type: Article

References (64)

1. Salomone S, Caraci F, Leggio GM, Fedotova J, Drago F (2012) New pharmacological strategies for treatment of Alzheimer’s disease: focus on disease modifying drugs. Br J Clin Pharmacol 73(4):504–517. doi:10.1111/j.1365-2125.2011.04134.x
2. Alzheimer’s Association (2015) 2015 Alzheimer’s disease facts and figures. Alzheimers Dement 11:332–384
3. Cummings J, Vinters H, Cole G, Khachaturian Z (1998) Alzheimer’s disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities. Neurology 1(Suppl 1):S2–17
4. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid β-peptide. Nat Rev Mol Cell Biol 8(2):101–112
5. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s Disease: progress and problems on the road to therapeutics. Science 297(5580):353–356. doi:10.1126/science.1072994
6. LaFerla FM, Oddo S (2005) Alzheimer’s disease: Aβ, tau and synaptic dysfunction. Trends Mol Med 11(4):170–176. doi:10.1016/j.molmed.2005.02.009
7. Braak H, Braak E (1991) Neuropathological staging of Alzheimer-related changes. Acta Neuropathol (Berl) 82:239–259
8. Ferretti L, McCurry S, Logsdon R, Gibbons L, Teri L (2001) Anxiety and Alzheimer’s disease. J Geriatr Psychiatry Neurol 14:52–58
9. Hwang TJ, Masterman DL, Ortiz F, Fairbanks LA, Cummings JL (2004) Mild cognitive impairment is associated with characteristic neuropsychiatric symptoms. Alzheimer Dis Assoc Disord 18(1):17–21
10. Apostolova LG, Cummings JL (2008) Neuropsychiatric manifestations in mild cognitive impairment: a systematic review of the literature. Dement Geriatr Cogn Disord 25(2):115–126
11. Mega MS, Cummings JL, Fiorello T, Gornbein J (1996) The spectrum of behavioral changes in Alzheimer’s disease. Neurology 46:130–135
12. Seignourel PJ, Kunik ME, Snow L, Wilson N, Stanley M (2008) Anxiety in dementia: a critical review. Clin Psychol Rev 28(7):1071–1082. doi:10.1016/j.cpr.2008.02.008
13. Sierksma ASR, van den Hove DLA, Steinbusch HWM, Prickaerts J (2010) Major depression, cognitive dysfunction and Alzheimer’s disease: is there a link? Eur J Pharmacol 626(1):72–82. doi:10.1016/j.ejphar.2009.10.021
14. Verkaik R, Nuyen J, Schellevis F, Francke A (2007) The relationship between severity of Alzheimer’s disease and prevalence of comorbid depressive symptoms and depression: a systematic review. Int J Geriatr Psychiatry 22:1063–1086
15. Weisenbach S, Boore L, HC K (2012) Depression and cognitive impairment in older adults. Curr Psychiatry Rep 14:280–288
16. Hogervorst E (2013) Effects of gonadal hormones on cognitive behaviour in elderly men and women. J Neuroendocrinol 25(11):1182–1195. doi:10.1111/jne.12080
17. Marshall KM (2011) Introduction to the interaction between gonadal steroids and the central nervous system. In: Neill CJ, Kulkarni J (eds) Biological basis of sex differences in psychopharmacology. Springer, Berlin Heidelberg, Berlin, Heidelberg, pp 1–13. doi:10.1007/7854_2011_136
18. Hogervorst E, Bandelow S, Combrinck M, Smith AD (2004) Low free testosterone is an independent risk factor for Alzheimer’s disease. Exp Gerontol 39(11–12):1633–1639. doi:10.1016/j.exger.2004.06.019
19. Short RA, O’Brien PC, Graff-Radford NR, Bowen RL (2001) Elevated gonadotropin levels in patients with Alzheimer disease. Mayo Clin Proc 76(9):906–909. doi:10.4065/76.9.906
20. Tsolaki M, Grammaticos P, Karanasou C, Balaris V, Kapoukranidou D, Kalpidis I, Petsanis K, Dedousi E (2005) Serum estradiol, progesterone, testosterone, FSH and LH levels in postmenopausal women with Alzheimer’s dementia. Hell J Nucl Med 8:39–42
21. Cherrier MM, Matsumoto AM, Amory JK, Asthana S, Bremner W, Peskind ER, Raskind MA, Craft S (2005) Testosterone improves spatial memory in men with Alzheimer disease and mild cognitive impairment. Neurology 64:2063–2068
22. Holland J, Bandelow S, Hogervorst E (2011) Testosterone levels and cognition in elderly men: a review. Maturitas 69(4):322–337. doi:10.1016/j.maturitas.2011.05.012
23. Lu PH, Masterman DA, Mulnard R, Cotman C, Miller B, Yaffe K, Reback E, Porter V et al (2006) Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men. Arch Neurol 63:177–185
24. Pike CJ, Carroll JC, Rosario ER, Barron AM (2009) Protective actions of sex steroid hormones in Alzheimer’s disease. Front Neuroendocrinol 30(2):239–258. doi:10.1016/j.yfrne.2009.04.015
25. Tan RS, Pu SJ (2003) A pilot study on the effects of testosterone in hypogonadal aging male patients with Alzheimer’s disease. Aging Male 6:13–17
26. Pike C, Rosario E, Nguyen T-V (2006) Androgens, aging, and Alzheimer’s disease. Endocr 29(2):233–241. doi:10.1385/ENDO:29:2:233
27. Moffat SD, Zondrman AB, Metter EJ, Kawas C, Blackman MR, Harman SM, Resnick SN (2004) Free testosterone and risk of Alzheimer’s disease in older men. Neurology 62:188–193
28. Altemus M (2006) Sex differences in depression and anxiety disorders: Potential biological determinants. Horm Behav 50(4):534–538. doi:10.1016/j.yhbeh.2006.06.031
29. Di Blasio CJ, Hammett J, Malcolm JB, Judge BA, Womack JH, Kincade MC, Ogles ML, Mancini JG et al (2008) Prevalence and predictive factors for the development of de novo psychiatric illness in patients receiving androgen deprivation therapy for prostate cancer. Can J Urol 15:4249–4256
30. McHenry J, Carrier N, Hull E, Kabbaj M (2014) Sex differences in anxiety and depression: role of testosterone. Front Neuroendocrinol 35(1):42–57. doi:10.1016/j.yfrne.2013.09.001
31. Frye CA, Walf AA (2009) Depression-like behavior of aged male and female mice is ameliorated with administration of testosterone or its metabolites. Physiol Behav 97(2):266–269. doi:10.1016/j.physbeh.2009.02.022
32. Herrera-Pérez JJ, Martínez-Mota L, Chavira R, Fernández-Guasti A (2012) Testosterone prevents but not reverses anhedonia in middle-aged males and lacks an effect on stress vulnerability in young adults. Horm Behav 61(4):623–630. doi:10.1016/j.yhbeh.2012.02.015
33. Wainwright SR, Lieblich SE, Galea LAM (2011) Hypogonadism predisposes males to the development of behavioural and neuroplastic depressive phenotypes. Psychoneuroendocrinology 36(9):1327–1341. doi:10.1016/j.psyneuen.2011.03.004
34. Carrier N, Kabbaj M (2012) Testosterone and imipramine have antidepressant effects in socially isolated male but not female rats. Horm Behav 61(5):678–685. doi:10.1016/j.yhbeh.2012.03.001
35. Rinnab L, Gust K, Hautmann RE, Küfer R (2009) Testosterone replacement therapy and prostate cancer. The current position 67 years after the Huggins myth. Urologe A 48(5):516–522. doi:10.1007/s00120-009-1954-z
36. Walsh JP, Kitchens AC (2015) Testosterone therapy and cardiovascular risk. Trends Cardiovasc Med 25(3):250–257. doi:10.1016/j.tcm.2014.10.014
37. Butchart J, Birch B, Bassily R, Wolfe L, Holmes C (2013) Male sex hormones and systemic inflammation in Alzheimer disease. Alzheimer Dis Assoc Disord 27(2):153–156. doi:10.1097/WAD.0b013e318258cd63
38. Davinelli S, Sapere N, Zella D, Bracale R, Intrieri M, Scapagnini G (2012) Pleiotropic protective effects of phytochemicals in Alzheimer’s disease. Oxid Med Cell Longev 2012:386527. doi:10.1155/2012/386527
39. Kim HG, Oh MS (2012) Herbal medicines for the prevention and treatment of Alzheimer’s disease. Curr Pharm Des 18:57–75
40. Fedotova J, Soultanov V, Nikitina T, Roschin V, Ordyan N, Hritcu L (2016) Cognitive-enhancing activities of the polyprenol preparation Ropren® in gonadectomized β-amyloid (25–35) rat model of Alzheimer’s disease. Physiol Behav 157:55–62. doi:10.1016/j.physbeh.2016.01.035
41. Blogger AC, Rubens JP, Roshchin VI (1989) Harvesting and utilization of tree foliage. IUFRO Project Group, Riga
42. Vasiliev VN, Roschin VI, Felece S (1996) Extracting compounds of Picea abies (L.) Karst. Rast Resursy 32:151–180
43. Bizzarri R, Cerbai B, Signori F, Solaro R, Bergamini E, Tamburini I, Chiellini E (2003) New perspectives for (S)-dolichol and (S)-nordolichol synthesis and biological functions. Biogerontology 4(6):353–363. doi:10.1023/B:BGEN.0000006555.87407.04
44. Swiezewska E, Danikiewicz W (2005) Polyisoprenoids: Structure, biosynthesis and function. Prog Lipid Res 44(4):235–258. doi:10.1016/j.plipres.2005.05.002
45. Choi D-Y, Lee Y-J, Hong JT, Lee H-J (2012) Antioxidant properties of natural polyphenols and their therapeutic potentials for Alzheimer’s disease. Brain Res Bull 87(2–3):144–153. doi:10.1016/j.brainresbull.2011.11.014
46. Cui X, Zuo P, Zhang Q, Li X, Hu Y, Long J, Packer L, Liu J (2006) Chronic systemic D-galactose exposure induces memory loss, neurodegeneration, and oxidative damage in mice: protective effects of R-alpha-lipoic acid. J Neurosci Res 83:1584–1590
47. Dumont M, Beal MF (2011) Neuroprotective strategies involving ROS in Alzheimer’s disease. Free Radic Biol Med 51(5):1014–1026. doi:10.1016/j.freeradbiomed.2010.11.026
48. Pronin A, Danilov L, Narovlyansky A, Sanin A (2014) Plant polyisoprenoids and control of cholesterol level. Arch Immunol Ther Exp (Warsz) 62(1):31–39. doi:10.1007/s00005-013-0253-y
49. Skorupinska-Tudek K, Wojcik J, Swiezewska E (2008) Polyisoprenoid alcohols—recent results of structural studies. Chem Rec 8:33–45
50. Fedotova I, Sultanov V, Kuznetsova N, Roshchin V, Nikitina T (2010) Effect of new polyprenol drug ropren on anxiety-depressive-like behavior in rats with experimental model Alzheimer disease. Eksp Klin Farmakol 73:2–5
51. Fedotova J, Soultanov V, Nikitina T, Roschin V, Ordayn N (2012) Ropren® is a polyprenol preparation from coniferous plants that ameliorates cognitive deficiency in a rat model of beta-amyloid peptide-(25–35)-induced amnesia. Phytomedicine 19(5):451–456. doi:10.1016/j.phymed.2011.09.073
52. Klementiev B, Novikova T, Novitskaya V, Walmod PS, Dmytriyeva O, Pakkenberg B, Berezin V, Bock E (2007) A neural cell adhesion molecule-derived peptide reduces neuropathological signs and cognitive impairment induced by Aβ25-35. Neuroscience 145(1):209–224. doi:10.1016/j.neuroscience.2006.11.060
53. Paxinos G, Watson C (2007) The rat brain in stereotaxic coordinates, 6th edn. Academic Press, London
54. Porsolt R, Anton G, Blavet N, Jalfre M (1978) Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 47:379–391
55. Fedotova J (2014) Blockade of D1 dopaminergic receptors corrects depression-like behaviour in gonadectomized rats treated with a low dose of testosterone. Eur Neuropsychopharmacol 24(2):363
56. Detke M, Rickels M, Lucki I (1995) Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology (Berl) 121:66–72
57. Swaab DF, Bao A-M, Lucassen PJ (2005) The stress system in the human brain in depression and neurodegeneration. Ageing Res Rev 4(2):141–194. doi:10.1016/j.arr.2005.03.003
58. Watson S, Gallagher P, Del-Estal D, Hearn A, Ferrier IN, Young AH (2002) Hypothalamic-pituitary-adrenal axis function in patients with chronic depression. Psychol Med 32:1021–1028
59. Young EA, Korszun A (2002) The hypothalamic-pituitary-gonadal axis in mood disorders. Endocrinol Metab Clin North Am 31:63–78
60. Bingaman E, Baeckman L, Yracheta J, Handa R, Gray T (1994) Localization of androgen receptor within peptidergic neurons of the rat forebrain. Brain Res Bull 35:379–382
61. Handa RJ, Burgess LH, Kerr JE, O’Keefe JA (1994) Gonadal steroid hormone receptors and sex differences in the hypothalamo-pituitary-adrenal axis. Horm Behav 28(4):464–476. doi:10.1006/hbeh.1994.1044
62. Handa RJ, Weiser MJ, Zuloaga DG (2009) A role for the androgen metabolite, 5α-androstane-3β,17β-diol, in modulating oestrogen receptor β-mediated regulation of hormonal stress reactivity. J Neuroendocrinol 21(4):351–358. doi:10.1111/j.1365-2826.2009.01840.x
63. Viau V, Lee P, Sampson J, Wu J (2003) A testicular influence on restraint-induced activation of medial parvocellular neurons in the paraventricular nucleus in the male rat. Endocrinology 144(7):3067–3075. doi:10.1210/en.2003-0064
64. Viau V (2002) Functional cross-talk between the hypothalamic-pituitary-gonadal and -adrenal axes. J Neuroendocrinology 14:506–513